Search Results - "Treon, S"

The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia by Cao, Y, Hunter, Z R, Liu, X, Xu, L, Yang, G, Chen, J, Patterson, C J, Tsakmaklis, N, Kanan, S, Rodig, S, Castillo, J J, Treon, S P

“…CXCR4(WHIM) somatic mutations are common Waldenstrom's Macroglobulinemia (WM), and are associated with clinical resistance to ibrutinib. We engineered WM cells…”
Get full text

Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications by GUPTA, D, TREON, S. P, SCHLOSSMAN, R. L, RICHARDSON, P, RALPH, P, WU, L, PAYVANDI, F, MULLER, G, STIRLING, D. I, ANDERSON, K. C, SHIMA, Y, HIDESHIMA, T, PODAR, K, TAI, Y. T, LIN, B, LENTZSCH, S, DAVIES, F. E, CHAUHAN, D

“…Increased angiogenesis has recently been recognized in active multiple myeloma (MM). Since vascular endothelial growth factor (VEGF) and basic fibroblast…”
Get full text

Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management by Terpos, E., Branagan, A.R., García-Sanz, R., Trotman, J., Greenberger, L.M., Stephens, D.M., Morel, P., Kimby, E., Frustaci, A.M., Hatjiharissi, E., San-Miguel, J., Dimopoulos, M.A., Treon, S.P., Leblond, V.

“…Consensus Panel 5 (CP5) of the 11th International Workshop on Waldenstrom's Macroglobulinemia (IWWM-11; held in October 2022) was tasked with reviewing the…”
Get full text

ERK1/2 pro‐survival signalling is suppressed by pirtobrutinib in ibrutinib‐resistant MYD88‐mutated lymphoma cells by Munshi, M., Liu, X., Kofides, A., Tsakmaklis, N., Hunter, Z. R., Guerrera, M. L., Canning, A., Gustine, J. N., Liu, S., Hatcher, J. M., Chen, J., Meid, K., Sarosiek, S., Flynn, C. A., Branagan, A. R., Keudell, G., Palomba, L. M., Castillo, J. J., Yang, G., Treon, S. P.

“…Summary Covalent Bruton's tyrosine kinase‐inhibitors (cBTK‐i) are highly active in MYD88‐mutated (MYD88Mut) Waldenstrom's macroglobulinaemia and suppress…”
Get full text

Detection of MYD88 L265P in peripheral blood of patients with Waldenström’s Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance by Xu, L, Hunter, Z R, Yang, G, Cao, Y, Liu, X, Manning, R, Tripsas, C, Chen, J, Patterson, C J, Kluk, M, Kanan, S, Castillo, J, Lindeman, N, Treon, S P

“…MYD88 L265P is highly prevalent in Waldenstrom’s Macroglobulinemia (WM) and IgM monoclonal gammopathy of unknown significance (MGUS). We investigated whether…”
Get full text

Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients by D'Sa, S, Matous, JV, Advani, R, Buske, C, Castillo, JJ, Gatt, M, Kapoor, P, Kersten, MJ, Leblond, V, Leiba, M, Palomba, ML, Paludo, J, Qiu, L, Sarosiek, S, Shadman, M, Talaulikar, D, Tam, CS, Tedeschi, A, Thomas, SK, Tohidi-Esfahani, I, Trotman, J, Varettoni, M, Vos, JMI, Garcia-Sanz, R, San-Miguel, J, Dimopoulos, MA, Treon, SP, Kastritis, E

“…The consensus panel 2 (CP2) of the 11th International Workshop on Waldenström's macroglobulinemia (IWWM-11) has reviewed and incorporated current data to…”
Get full text

Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia by Garcia-Sanz, Ramón, Varettoni, Marzia, Jiménez, Cristina, Ferrero, Simone, Poulain, Stephanie, San-Miguel, Jesus F., Guerrera, Maria L., Drandi, Daniela, Bagratuni, Tina, McMaster, Mary, Roccaro, Aldo M., Roos-Weil, Damien, Leiba, Merav, Li, Yong, Qiu, Luigi, Hou, Jian, De Larrea, C. Fernandez, Castillo, Jorge J., Dimopoulos, M., Owen, R.G., Treon, S.P., Hunter, Z.R.

“…Apart from the MYD88L265P mutation, extensive information exists on the molecular mechanisms in Waldenström's Macroglobulinemia and its potential utility in…”
Get full text

Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials by Tam, CS, Kapoor, P, Castillo, JJ, Buske, C, Ansell, SM, Branagan, AR, Kimby, E, Li, Y, Palomba, ML, Qiu, L, Shadman, M, Abeykoon, JP, Sarosiek, S, Vos, JMI, Yi, S, Stephens, D, Roos-Weil, D, Roccaro, AM, Morel, P, Munshi, NC, Anderson, KC, San-Miguel, J, Garcia-Sanz, R, Dimopoulos, MA, Treon, SP, Kersten, MJ

“…Recent advances in the understanding of Waldenström macroglobulinemia (WM) biology have impacted the development of effective novel agents and improved our…”
Get full text

Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy by Hideshima, Teru, Chauhan, Dharminder, Shima, Yoshihito, Raje, Noopur, Davies, Faith E., Tai, Yu-Tzu, Treon, Steven P., Lin, Boris, Schlossman, Robert L., Richardson, Paul, Muller, George, Stirling, David I., Anderson, Kenneth C.

“…Although thalidomide (Thal) was initially used to treat multiple myeloma (MM) because of its known antiangiogenic effects, the mechanism of its anti-MM…”
Get full text

Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia by Treon, S. P., Branagan, A. R., Hunter, Z., Santos, D., Tournhilac, O., Anderson, K. C.

“…Background: The anti-CD20 monoclonal antibody rituximab is an important therapeutic in Waldenstrom's macroglobulinemia (WM), producing response rates of…”
Get full text

Clonal B cells in Waldenström’s macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling by Argyropoulos, K V, Vogel, R, Ziegler, C, Altan-Bonnet, G, Velardi, E, Calafiore, M, Dogan, A, Arcila, M, Patel, M, Knapp, K, Mallek, C, Hunter, Z R, Treon, S P, van den Brink, M R M, Palomba, M L

“…Waldenström’s macroglobulinemia (WM) is a B-cell non-Hodgkin’s lymphoma (B-NHL) characterized by immunoglobulin M (IgM) monoclonal gammopathy and the medullary…”
Get full text

Extended rituximab therapy in Waldenström's macroglobulinemia by TREON, S. P, EMMANOUILIDES, C, KIMBY, E, KELLIHER, A, PREFFER, F, BRANAGAN, A. R, ANDERSON, K. C, FRANKEL, S. R

“…Waldenström's macroglobulinemia (WM) is a CD20 expressing B-cell malignancy represented by the pathological diagnosis of IgM secreting lymphoplasmacytic…”
Get full text

Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling by Tournilhac, O., Santos, D. D., Xu, L., Kutok, J., Tai, Y.-T., Le Gouill, S., Catley, L., Hunter, Z., Branagan, A. R., Boyce, J. A., Munshi, N., Anderson, K. C., Treon, S. P.

“…Bone marrow (BM) mast cells (MC) are commonly found in association with lymphoplasmacytic cells (LPC) in patients with Waldenström's macroglobulinemia (WM)…”
Get full text

Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia by Ghobrial, I M, Redd, R, Armand, P, Banwait, R, Boswell, E, Chuma, S, Huynh, D, Sacco, A, Roccaro, A M, Perilla-Glen, A, Noonan, K, MacNabb, M, Leblebjian, H, Warren, D, Henrick, P, Castillo, J J, Richardson, P G, Matous, J, Weller, E, Treon, S P

“…We examined the combination of the mammalian target of rapamycin inhibitor everolimus with bortezomib and rituximab in patients with relapsed/refractory…”
Get full text

Autologous and allogeneic stem‐cell transplantation for transformed Waldenström macroglobulinemia by Durot, E., Kanagaratnam, L., Zanwar, S., Kaufman, A., D'Sa, S., Toussaint, E., Roos‐Weil, D., Alcoceba, M., Vos, J. M., Hivert, B., Michallet, A., Talaulikar, D., Kastritis, E., Protin, C., Abeykoon, J. P., Dupuis, J., Leprêtre, S., Khwaja, J., Roussel, X., Regny, C., Treon, S. P., Garcia‐Sanz, R., Morel, P., Munoz, J., Castillo, J. J., Kapoor, P., Delmer, A.

Get full text

miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth by Fulciniti, M, Amodio, N, Bandi, R L, Cagnetta, A, Samur, M K, Acharya, C, Prabhala, R, D'Aquila, P, Bellizzi, D, Passarino, G, Adamia, S, Neri, A, Hunter, Z R, Treon, S P, Anderson, K C, Tassone, P, Munshi, N C

“…Deregulated microRNA (miR)/transcription factor (TF)-based networks represent a hallmark of cancer. We report here a novel c-Myc/miR-23b/Sp1 feed-forward loop…”
Get full text

Characterization of familial Waldenstrom's macroglobulinemia by TREON, S. P, HUNTER, Z. R, TOURNILHAC, O, PATTERSON, C. J, MANNING, R, BRANAGAN, A. R, MORTON, C. C, AGGARWAL, A, EWEN, E. P, MASOTA, S, LEE, C, DITZEL SANTOS, D, HATJIHARISSI, E, XU, L, LELEU, X

“…Familial clustering of B-cell disorders among Waldenström's macroglobulinemia (WM) patients has been reported, though the frequency and any differences in…”
Get full text

PRELIMINARY CLINICAL DATA FROM A PHASE 1B STUDY OF MAVORIXAFOR AND IBRUTINIB IN PATIENTS WITH WALDENSTRöM MACROGLOBULINEMIA WITH MYD88 AND CXCR4 MUTATIONS by Treon, S., Buske, C., Thomas, S., Branagan, A., Dimopoulos, M., Castillo, J. J., Garzon, F., Tang, W., Ronan, R., Seyffert, S., Garg, V., Ali, S., Taveras, A., Badarau, A., Zmajkovicova, K., Maier, S., Maierhofer, B., Matous, J.

Get full text

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications by Mitsiades, Constantine S., Treon, Steven P., Mitsiades, Nicholas, Shima, Yoshihito, Richardson, Paul, Schlossman, Robert, Hideshima, Teru, Anderson, Kenneth C.

“…Multiple myeloma (MM) remains incurable and novel treatments are urgently needed. Preclinical in vitro and in vivo evaluations were performed to assess the…”
Get full text

Update on treatment recommendations from the Third International Workshop on Waldenström's Macroglobulinemia by Treon, Steven P., Gertz, Morie A., Dimopoulos, Meletios, Anagnostopoulos, Athanasios, Blade, Joan, Branagan, Andrew R., Garcia-Sanz, Ramon, Johnson, Stephen, Kimby, Eva, LeBlond, Veronique, Fermand, Jean-Paul, Maloney, David G., Merlini, Giampaolo, Morel, Pierre, Morra, Enrica, Nichols, Gwen, Ocio, Enrique M., Owen, Roger, Stone, Marvin J.

“…Waldenström macroglobulinemia (WM) is a B-cell disorder characterized by the infiltration of lymphoplasmacytic cells into bone marrow and the presence of an…”
Get full text